Incannex Healthcare Inc. Research and Development Expense
Incannex Healthcare Inc. (IXHL) reported Research and Development Expense of $321.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-15
- Incannex Healthcare Inc. research and development expense for the quarter ending 2026-03-31 was $321.00K, a 88.26% decline year-over-year.
- Incannex Healthcare Inc. research and development expense for the quarter ending 2025-12-31 was $2.28M, a 61.24% increase year-over-year.
- Incannex Healthcare Inc. research and development expense for the quarter ending 2025-09-30 was $1.12M, a 61.33% decline year-over-year.
- Incannex Healthcare Inc. research and development expense for the quarter ending 2025-06-30 was $3.70M, a 15.07% decline year-over-year.
- Incannex Healthcare Inc. research and development expense for fiscal 2025 was $10.75M, a 16.55% decline from fiscal 2024.
- Incannex Healthcare Inc. research and development expense for fiscal 2024 was $12.88M, a 104.14% increase from fiscal 2023.
- Incannex Healthcare Inc. research and development expense for fiscal 2023 was $6.31M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $321.00K 10-Q · filed 2026-05-15 | $2.60M derived: sum of 2 quarters · filed 2026-05-15 | $3.72M 10-Q · filed 2026-05-15 | $7.42M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $2.28M 10-Q · filed 2026-02-13 | $3.40M 10-Q · filed 2026-02-13 | $7.10M derived: sum of 3 quarters · filed 2026-02-13 | $9.84M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-09-30 | $1.12M 10-Q · filed 2025-11-14 | $4.82M derived: sum of 2 quarters · filed 2025-11-14 | $7.56M derived: sum of 3 quarters · filed 2026-05-15 | $8.97M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $6.44M derived: sum of 2 quarters · filed 2026-05-15 | $7.85M derived: sum of 3 quarters · filed 2026-05-15 | $10.75M 10-K · filed 2025-09-29 |
| 2025-03-31 | $2.73M 10-Q · filed 2026-05-15 | $4.15M derived: sum of 2 quarters · filed 2026-05-15 | $7.04M 10-Q · filed 2026-05-15 | $11.40M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.41M 10-Q · filed 2026-02-13 | $4.31M 10-Q · filed 2026-02-13 | $8.67M derived: sum of 3 quarters · filed 2026-02-13 | $11.95M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $2.90M 10-Q · filed 2025-11-14 | $7.25M derived: sum of 2 quarters · filed 2025-11-14 | $10.53M derived: sum of 3 quarters · filed 2025-11-14 | $13.17M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $7.64M derived: sum of 2 quarters · filed 2025-09-29 | $10.27M derived: sum of 3 quarters · filed 2025-09-29 | $12.88M 10-K · filed 2025-09-29 |
| 2024-03-31 | $3.28M 10-Q · filed 2025-05-15 | $5.92M derived: sum of 2 quarters · filed 2025-05-15 | $8.52M 10-Q · filed 2025-05-15 | $10.23M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.64M 10-Q · filed 2025-02-14 | $5.25M 10-Q · filed 2025-02-14 | $6.96M derived: sum of 3 quarters · filed 2025-02-14 | $8.60M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $2.61M 10-Q · filed 2024-11-14 | $4.32M derived: sum of 2 quarters · filed 2024-11-14 | $5.96M derived: sum of 3 quarters · filed 2024-11-14 | $7.51M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $3.35M derived: sum of 2 quarters · filed 2024-09-30 | $4.90M derived: sum of 3 quarters · filed 2024-09-30 | $6.31M 10-K · filed 2024-09-30 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-15 | $3.19M derived: sum of 2 quarters · filed 2024-05-15 | $4.60M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $1.55M 10-Q · filed 2024-02-14 | $2.96M 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |